Matches in Wikidata for { <http://www.wikidata.org/entity/Q91968940> ?p ?o ?g. }
- Q91968940 description "2019 թվականի դեկտեմբերի 10-ին հրատարակված գիտական հոդված" @default.
- Q91968940 description "article scientifique publié en 2019" @default.
- Q91968940 description "artículu científicu espublizáu n'avientu de 2019" @default.
- Q91968940 description "im Dezember 2019 veröffentlichter wissenschaftlicher Artikel" @default.
- Q91968940 description "scientific article published on 10 December 2019" @default.
- Q91968940 description "wetenschappelijk artikel" @default.
- Q91968940 description "наукова стаття, опублікована 10 грудня 2019" @default.
- Q91968940 name "Predictors of progression free survival, overall survival and early cessation of chemotherapy in women with potentially platinum sensitive (PPS) recurrent ovarian cancer (ROC) starting third or subsequent line(≥3) chemotherapy - The GCIG symptom ben" @default.
- Q91968940 name "Predictors of progression free survival, overall survival and early cessation of chemotherapy in women with potentially platinum sensitive (PPS) recurrent ovarian cancer (ROC) starting third or subsequent line(≥3) chemotherapy - The GCIG symptom ben" @default.
- Q91968940 type Item @default.
- Q91968940 label "Predictors of progression free survival, overall survival and early cessation of chemotherapy in women with potentially platinum sensitive (PPS) recurrent ovarian cancer (ROC) starting third or subsequent line(≥3) chemotherapy - The GCIG symptom ben" @default.
- Q91968940 label "Predictors of progression free survival, overall survival and early cessation of chemotherapy in women with potentially platinum sensitive (PPS) recurrent ovarian cancer (ROC) starting third or subsequent line(≥3) chemotherapy - The GCIG symptom ben" @default.
- Q91968940 prefLabel "Predictors of progression free survival, overall survival and early cessation of chemotherapy in women with potentially platinum sensitive (PPS) recurrent ovarian cancer (ROC) starting third or subsequent line(≥3) chemotherapy - The GCIG symptom ben" @default.
- Q91968940 prefLabel "Predictors of progression free survival, overall survival and early cessation of chemotherapy in women with potentially platinum sensitive (PPS) recurrent ovarian cancer (ROC) starting third or subsequent line(≥3) chemotherapy - The GCIG symptom ben" @default.
- Q91968940 P1433 Q91968940-460D00EE-C1D2-4FB3-916D-5EF999E8642D @default.
- Q91968940 P1476 Q91968940-981CF2DB-FE20-4DEC-B2B8-F3436287097A @default.
- Q91968940 P2093 Q91968940-00778892-D450-4010-BFC9-41F4EEF0B20D @default.
- Q91968940 P2093 Q91968940-04ACA050-8863-4ADA-BAB0-249EF7BCF42E @default.
- Q91968940 P2093 Q91968940-07236D84-4B72-4FB2-AD92-9B1187DA6930 @default.
- Q91968940 P2093 Q91968940-07500052-F366-43A9-9DAE-7FCE41CB92F6 @default.
- Q91968940 P2093 Q91968940-1F6C5920-005E-454A-A1EC-FF56DE91B377 @default.
- Q91968940 P2093 Q91968940-214B6D5D-D222-4DED-A43C-762672CF1DCE @default.
- Q91968940 P2093 Q91968940-3B61496F-FDBE-4399-8CB8-E1E73A9B8368 @default.
- Q91968940 P2093 Q91968940-3C00CB09-95A5-430D-9A83-A4F139468FC9 @default.
- Q91968940 P2093 Q91968940-49FDE906-4701-4B09-B8A9-EEB6A0D70BBA @default.
- Q91968940 P2093 Q91968940-4D2749AB-2F8C-45D0-91C0-1D440D064558 @default.
- Q91968940 P2093 Q91968940-56E948C3-3B9C-4B0A-97B3-811A102D5CAA @default.
- Q91968940 P2093 Q91968940-89A01BE7-CAB9-4AC4-918C-D23B53F078B5 @default.
- Q91968940 P2093 Q91968940-8AF62315-AA09-4464-B7C2-DA5B1B34BA33 @default.
- Q91968940 P2093 Q91968940-8B0FDC24-5A0C-409F-877A-A5E435ACA931 @default.
- Q91968940 P2093 Q91968940-A64AC8E0-56CE-4B64-9C42-66ABEF4AD571 @default.
- Q91968940 P2093 Q91968940-B49C96A1-289B-41A5-A909-7863DA339CA6 @default.
- Q91968940 P2093 Q91968940-D98C63D0-4723-4EF8-B54E-24E943B1D3D8 @default.
- Q91968940 P2093 Q91968940-DA2FAFFF-5555-44F9-BBC9-EE6DE5A0D4CF @default.
- Q91968940 P2093 Q91968940-EFDB86FF-3B19-4040-8F3B-A7376492CAFC @default.
- Q91968940 P2860 Q91968940-1D4BD06E-F29E-4BE0-AD79-194D26494B90 @default.
- Q91968940 P2860 Q91968940-1FD3A516-4D6F-4025-9A67-9AC2CB15CE0D @default.
- Q91968940 P2860 Q91968940-313852FB-0E9A-4F3E-A196-AA64AA6D5A95 @default.
- Q91968940 P2860 Q91968940-4513BCD6-A93C-4E40-B51E-DCD012D22524 @default.
- Q91968940 P2860 Q91968940-4DBDDC4F-81E2-4FDB-AB3E-7F6AD7291AA9 @default.
- Q91968940 P2860 Q91968940-6EC58EF7-AD76-44E4-A38D-422C2DFF80FA @default.
- Q91968940 P2860 Q91968940-7424009B-8E45-4318-A947-4C6FC6195FE8 @default.
- Q91968940 P2860 Q91968940-9F77F6AF-FA60-4DC5-B1D4-21E1963B7F78 @default.
- Q91968940 P2860 Q91968940-A30AFC3D-CBE9-4C26-A6AF-116BC00A167A @default.
- Q91968940 P2860 Q91968940-CFCA2D60-6E11-4593-B9FA-232FFEDFF387 @default.
- Q91968940 P2860 Q91968940-E83CCB72-106E-4F97-9027-A569E373D92B @default.
- Q91968940 P2860 Q91968940-F035E365-73AB-47F9-8802-E8D43B782459 @default.
- Q91968940 P2860 Q91968940-F04C741A-42CC-493E-9DD1-8411D8C91505 @default.
- Q91968940 P2860 Q91968940-F14CD108-7451-40B8-AD83-962B7ABA9BC7 @default.
- Q91968940 P2860 Q91968940-F4341A47-0BE7-4302-B937-D6E2D9EED0FD @default.
- Q91968940 P2860 Q91968940-F77CE124-6303-4492-82FF-AE15AC2E54C7 @default.
- Q91968940 P2860 Q91968940-FE09CD42-7E9E-4941-AE1D-520EF1275C70 @default.
- Q91968940 P304 Q91968940-390D7DE8-2AA6-47BA-B9CA-FE131FD47F31 @default.
- Q91968940 P31 Q91968940-6ABEB739-C25F-4DBB-9334-341424DFDF9F @default.
- Q91968940 P356 Q91968940-DF7C08FA-8F2E-4B29-A3F1-872309B6C3A7 @default.
- Q91968940 P433 Q91968940-663A43A0-3C83-4DEA-B131-F48DF5C7C023 @default.
- Q91968940 P478 Q91968940-69AE1F58-6B7E-45D5-92B8-7961B1FCE770 @default.
- Q91968940 P577 Q91968940-A36EAE06-939E-44DB-BC6F-CAC75B36F1B8 @default.
- Q91968940 P698 Q91968940-D3148E55-51B8-4C2F-A0A9-A06E8623B4DB @default.
- Q91968940 P921 Q91968940-20E0CB12-4156-425D-BB4E-E9850AA1A10F @default.
- Q91968940 P921 Q91968940-59FF47DD-407C-4F33-BE1A-6F8B8A939DB5 @default.
- Q91968940 P356 J.YGYNO.2019.10.001 @default.
- Q91968940 P698 31836184 @default.
- Q91968940 P1433 Q5625182 @default.
- Q91968940 P1476 "Predictors of progression free survival, overall survival and early cessation of chemotherapy in women with potentially platinum sensitive (PPS) recurrent ovarian cancer (ROC) starting third or subsequent line(≥3) chemotherapy - The GCIG symptom benefit study (SBS)" @default.
- Q91968940 P2093 "A Lanceley" @default.
- Q91968940 P2093 "A Okamoto" @default.
- Q91968940 P2093 "A Oza" @default.
- Q91968940 P2093 "C Roemer-Becuwe" @default.
- Q91968940 P2093 "E Aotani" @default.
- Q91968940 P2093 "E Avall-Lundqvist" @default.
- Q91968940 P2093 "F Hilpert" @default.
- Q91968940 P2093 "F Joly" @default.
- Q91968940 P2093 "F T Roncolato" @default.
- Q91968940 P2093 "J Berek" @default.
- Q91968940 P2093 "J Ledermann" @default.
- Q91968940 P2093 "L Buizen" @default.
- Q91968940 P2093 "M L Friedlander" @default.
- Q91968940 P2093 "M R Stockler" @default.
- Q91968940 P2093 "M T King" @default.
- Q91968940 P2093 "P Donnellan" @default.
- Q91968940 P2093 "R L O'Connell" @default.
- Q91968940 P2093 "T Fehm" @default.
- Q91968940 P2093 "V Salutari" @default.
- Q91968940 P2860 Q29615701 @default.
- Q91968940 P2860 Q29619615 @default.
- Q91968940 P2860 Q33846615 @default.
- Q91968940 P2860 Q34267336 @default.
- Q91968940 P2860 Q34422265 @default.
- Q91968940 P2860 Q34959939 @default.
- Q91968940 P2860 Q36166812 @default.
- Q91968940 P2860 Q36912591 @default.
- Q91968940 P2860 Q38736093 @default.
- Q91968940 P2860 Q39086297 @default.
- Q91968940 P2860 Q45778109 @default.
- Q91968940 P2860 Q46121510 @default.
- Q91968940 P2860 Q47237809 @default.
- Q91968940 P2860 Q52236134 @default.
- Q91968940 P2860 Q67989907 @default.
- Q91968940 P2860 Q73948160 @default.